Category Archives: Gene

Austrianova Secures Significant Investment from Real Tech Fund

 

SINGAPORE, 2021-Jul-7 — /EPR BIOTECH NEWS/ — Austrianova (the SG Austria group, Austrianova Singapore and Austrianova Thailand) is pleased and honoured to announce that, after extensive due diligence, Real Tech Fund (managed by Real Tech Holdings, Japan) has invested an undisclosed seven figure amount in Austrianova via its Real Tech Global Fund 1 to accelerate Austrianova’s growth. Real Tech Fund is a venture capital firm that invests specifically in innovative deep-technology startups mainly in Japan and Southeast Asia. Austrianova was assisted in this transaction by Square Associates. The financing from Real Tech coincides with, as well as bolsters, the Company’s next stage of growth in production capacity in order to satisfy the strong demand witnessed across the wide variety of applications that its unique protective cell encapsulation technology addresses. It also enhances and facilitates Austrianova’s entry into the Japanese market and specifically partnerships with clients benefiting from Austrianova’s Cell-ina-Box® and Bac-in-a-Box® technologies.

“We are pleased that Real Tech has decided to invest in Austrianova as well as that they are convinced of the value of the Cell-in-a-Box® and Bac-in-a-Box® technologies for solving serious problems faced by the planet and by humanity” stated Walter H Gunzburg, Chairman of Austrianova. “Real Tech already has proven to be a valued partner as well as a significant investor in Austrianova and we look forward to working closely together in the future” added Brian Salmons, CEO of Austrianova.

 

About Austrianova
Austrianova (the SG Austria Group), is a biotech company with a global footprint and operations in Singapore and Thailand. Austrianova utilizes a novel and proprietary technology for the encapsulation of living mammalian (Cell-in-a-Box®) and bacterial (Bac-in-a-Box®) cells. Cell-in-a-Box® protects the encapsulated cells from rejection by the immune system, allows cells to be easily transported, stored and implanted at specific sites in patients. The
technology, which has been proven safe and efficacious in clinical trials carried out in Europe, allows companies to develop any kind of cells as a one-for-all living pharmaceutical. Bac-in-a-Box® is a similar protective device adapted for encapsulation of probiotic bacteria where it has human food and animal feed applications as well as rebalancing the microbiome due to its ability to extend storage under lyophilized conditions and to protect encapsulated bacteria against destruction by stomach acid. Austrianova now also offers GMP4Cells that includes competitively priced Master Cell Bank and Working Cell Bank production as well as “Fill and Finish” services for cell therapy products (such as stem cell therapies, biologics produced from cells e.g. vaccines, antibodies, enzymes, recombinant proteins, exosomes etc).

About Real Tech
Real Tech Holdings / Real Tech Fund is a joint venture fund between euglena Co.,Ltd and Leave a Nest Co., Ltd.  It supports change makers who give their heart and soul to solve societal and environmental challenges. Real Tech Holding’s manages Real Tech Fund, Japan’s leading deep-tech focused venture capital fund.
For more information: https://www.realtech.holdings

Forward-Looking Statements
This release includes forward-looking statements regarding Austrianova (the Company) and its respective businesses. Such statements are based on the current expectations of the management of each entity. The forward-looking events and circumstances discussed in this release, including completion of the public offering, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks affecting the Company, economic factors and the equity markets generally. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Austrianova undertakes no obligation to publicly update or revise any forwardlooking statement, whether as a result of new information, future events, or otherwise. This is not an offer or solicitation to buy or sell any securities.

Financial Information Contact: pierre.faddoul@square-associates.com
Company and Technology Contact: salmons@sgaustria.com
For more information: http://www.austrianova.com

SOURCE Austrianova

Complete protection of probiotics from destruction by stomach acid using Bac-in-a-Box technology

SINGAPORE, 2020-Nov-30 — /EPR BIOTECH NEWS/ — Austrianova announced today that a key publication on the ability of its patented technology, Bac-in-a-Box®, to completely protect probiotics from acidic conditions found in the stomach has been published in the well respected journal “Microbial Cell Factories”
https://rdcu.be/cbn0O.

Stomach acid is nature’s way of ensuring that any microbes in food are killed before they reach the intestines. In the same way, stomach acid is also a formidable barrier to the delivery of beneficial bacteria and yeast such as probiotics to the gut, necessitating the current million times “overdosing” of such bacteria. Even then, only a tiny fraction of probiotics survive transit through the stomach. The currently available protections and coatings are only partially effective and still result in the loss of millions of bacteria and the search is still on for novel protective agents and technologies to improve on this.

The stringently reviewed data presented in Austrianova’s Microbial Cell Factories paper show that Bac-in-a-Box® protects living micro-organisms (including probiotics) from stomach acid and bile, enabling them to reach the intestine in a viable state, thereby resulting in a greater beneficial effect. It also allows the use of ten thousand times lower doses, contributing to cost effectivity. Thus, Bac-in-a-Box® is ideal for enhanced and effective delivery of probiotics as well as of oral living vaccines, and it can even be used for microbial fecal transplantation (FMT or bacteriotherapy) where it provides a more patient friendly and acceptable means of delivering stool microbiota.

Brian Salmons, CEO of Austrianova, said “We are pleased that our publication on acid protection of encapsulated microbes has been published in Microbial Cell Factories, an open access, peer-reviewed journal, published by Springer Nature, that is the world leading, primary research journal fully focusing on Applied Microbiology.”

Elaborating on the significance of the paper, Prof. Walter H. Gunzburg said “The gut microbiota in humans and animals plays a key role in health by aiding digestion as well as regulating the immune system and protecting against disease causing pathogens. In recent years, changes or imbalances in the gut microbiota (dysbiosis) have been linked to many diseases as disparate as irritable bowel syndrome, dementia and diabetes, and evidence is
growing that restoring the balance of the microbiota by delivery of probiotic microorganisms can improve health. Orally delivered micro-organisms must survive transit through lethal, highly acid conditions in the stomach and current methods to protect probiotic microorganisms are still not effective enough. This paper reports that Austrianova’s proprietary encapsulation technology, Bac-in-a-Box®, protects members of the microbiota from stomach acid and bile. A number of probiotic strains were shown to survive low pH in vitro for at least 4 hours without appreciable loss in viability as compared to their respective non-encapsulated counterparts. Moreover, animal studies reveals that once the capsules arrive in the intestine (the site where they are needed to have beneficial effects), the probiotics are released and colonize the intestinal tract. Thus, Bac-in-a-Box® protects bacteria and yeasts from viability losses due to stomach acid, allowing the use of lower oral doses of probiotics and microbiota, whilst ensuring good intestinal delivery and release.”

About Austrianova
Austrianova, part of the SG Austria Group, is a biotech company with a global footprint and headquarters in Singapore. Austrianova utilizes a novel and proprietary technology for the encapsulation of living mammalian (Cell-in-a-Box®) and bacterial (Bac-in-a-Box®) cells. Cell-in-a-Box® protects the encapsulated cells from rejection by the immune system, allows cells to be easily transported, stored and implanted at specific sites in patients. The technology, which has been proven safe and efficacious in clinical trials carried out in Europe, allows companies to develop any kind of cells as a one-for-all living pharmaceutical. Bac-in-a-Box® is a similar protective device adapted for encapsulation of probiotic bacteria where it has human food and animal feed applications due to its ability to extend storage under lyophilized conditions and to protect encapsulated bacteria against destruction by stomach acid. Austrianova now also offers GMP4Cells that includes competitively priced Master Cell Bank and Working Cell Bank production as well as “Fill and Finish” services for cell therapy products (such as stem cell therapies, biologics produced from cells e.g. vaccines, antibodies, recombinant proteins etc).

Logo:

Austrianova logo

Cells for Cells and Austrianova announce publication on novel method to produce stem cell exosomes

SINGAPORE, 2020-May-22 — /EPR BIOTECH NEWS/ — Austrianova and Cells for Cells have just jointly published a ground breaking, peer reviewed, scientific publication on a novel, cost and time-saving method to generate extra-cellular vesicles (EVs) from encapsulated Mesenchymal Stem Cells (MSCs). These EVs are known to mediate many of the therapeutic effects of stem cells. The authors show that Austrianova’s proprietary Cell-in-a-Box encapsulation technology can be used to produce and deliver EVs from encapsulated MSC’s, as demonstrated using Cells for Cells proprietary MSCs.  The publication, which was co-authored with their academic partners, the University of the Andes, Chile and the University of Veterinary Medicine Vienna, Austria appeared in prestigious international journal “Frontiers in Pharmacology” (Front. Pharmacol., 21 May 2020 | https://doi.org/10.3389/fphar.2020.00679   https://www.frontiersin.org/articles/10.3389/fphar.2020.00679/full)

Currently, EVs have to be purified from cell culture conditioned media using tedious, costly and time-consuming protocols that are difficult to perform under Good Manufacturing Practices (GMP) conditions. The Cell-in-a-BoxÒ encapsulation technology allows efficient enrichment of EVs at high concentration since they are released from the encapsulated cells via the semipermeable pores, which selectively enable the release of small particles but not of the MSCs. Moreover, Cell-in-a-BoxÒ provides 3D culture conditions for the MSCs. The technology can be used in cell culture allowing GMP production. Alternatively, the encapsulated cells can be implanted into patients as a retrievable delivery device that shields the cells from clearance, whilst they continuously produce EVs, growth factors, hormones and other small therapeutically relevant molecules. Moreover, the EVs produced after encapsulation can themselves be used as drug-loaded delivery vehicles. This technology will be invaluable for the treatment of regenerative diseases and Inflammatory disease.

Maroun Khoury, CSO of Cells for Cells said “this is a multifaceted project bringing together different expertise  to support the burgeoning field of EV-based therapies. It will be interesting to test in the near future, the continuous  release of EVs in a in vivo context. At a personal level, it was  a great way to stay connected with colleagues that I met while living in Singapore ”.

Brian Salmons, CEO of Austrianova said “we are pleased that these results representing the culmination of a long term project with our colleagues at Cells for Cells are finally publicly available. The encapsulation of stem cells as a means to produce exosomes using our Cell-in-a-BoxÒ is an exciting technological breakthrough that is applicable for all stem cell types.”

About Austrianova

Austrianova, part of the SG Austria Group, is a biotech company with a global footprint and headquarters in Singapore. Austrianova utilizes a novel and proprietary technology for the encapsulation of living mammalian (Cell-in-a-Box®) and bacterial (Bac-in-a-Box®) cells. Cell-in-a-Box® protects the encapsulated cells from rejection by the immune system, allows cells to be easily transported, stored and implanted at specific sites in patients. The technology, which has been proven safe and efficacious in clinical trials carried out in Europe, allows companies to develop any kind of cells as a one-for-all living pharmaceutical. Bac-in-a-Box® is a similar protective device adapted for encapsulation of probiotic bacteria where it has human food and animal feed applications due to its ability to extend storage under lyophilized conditions and to protect encapsulated bacteria against destruction by stomach acid. Austrianova now also offers GMP4Cells that includes competitively priced Master Cell Bank and Working Cell Bank production as well as “Fill and Finish” services for cell therapy products (such as stem cell therapies, biologics produced from cells e.g. vaccines, antibodies, recombinant proteins etc).

About Cells for Cells

Cells for Cells is a Chilean biotechnological company dedicated to the research, development and commercialization of innovative cellular therapies, complying with high standards of scientific, technological and international quality, through manufacturing processes certified under ISO 9001: 2015. Each therapy is produced in our labs with GMP standards, being the first biotech company, with such high-quality standards at Latin American level. Our therapies are applied by duly certified specialists.

Logos:

Regenexx Announces the Publication of “Orthopedics 2.0 – How Regenerative Medicine and Interventional Orthopedics will Change Everything” on Amazon Kindle

Broomfield, CO, February 02, 2015 — /EPR BIOTECH NEWS/ — With more than 40,000 downloads, “Orthopedics 2.0 – How Regenerative Medicine and Interventional Orthopedics will Change Everything” is now available on Amazon Kindle. The third edition of the top-selling e-book is being offered as a free download through Jan. 6, 2015.

Written by Dr. Chris Centeno, this e-book delves into the human musculoskeletal system and explains how everything works together in concert to maintain our physical wellbeing. When a single component in this chain is damaged, it can lead to a cascade of joint, spine and connective tissue problems, resulting in chronic pain.

Using the Regenexx SANS approach, Orthopedics 2.0 walks you through a series of tests and exercises that you can do on your own to better understand where your own body is struggling to maintain proper stability and alignment, explaining the possible reasons and long term implications along the way. Orthopedics 2.0 also explores how Regenexx is pioneering the new field of Interventional Orthopedics, where the use of regenerative biologic treatments, such as adult stem cell therapy and platelet rich plasma, are being used to help repair and strengthen damaged tissues, as opposed to invasive surgeries that often remove important tissues when a joint or the spine becomes damaged.

With hyperlinks to more detailed information, related studies and commentary, this book condenses a vast amount of data and resources into an enjoyable and entertaining read.

About Regenexx
Since its genesis in 2005, Regenexx has been a world-leader in the use of adult stem cell treatments for orthopedic conditions, providing non-surgical, biologic therapies delivered with high accuracy through a needle. Regenexx has collected and published more data on stem cell patients than any other company and are dedicated to reinventing orthopedic care to help patients avoid invasive surgery.

Featured on television and media outlets such as the Doctors TV show, ABC News, Good Morning America and many others, Regenexx is taking orthopedic stem cell therapy to an exciting new level.

For more information about this e-book or to talk with a Regenexx Liaison, please call 888-525-3005 or email info@regenexx.com. Visit Regenexx online at:http://www.regenexx.com/

Contact-Details: Regenexx
Contact: Mark Testa
403 Summit Blvd., Suite 201
Broomfield, CO 80021
Phone: 888.525.3005
Email: info@regenexx.com
Web – http://www.regenexx.com/

Via EPR Network
More Biotech press releases

LC Sciences Launches Online Searchable Knowledgebase

LC Sciences, LLC, a leading provider of microRNA analysis services, today announced the launch of a new online searchable knowledgebase that researchers can use to locate technical information on the company’s website. This announcement comes on the heels of the launch of LC Sciences’ re-designed company website last week. The knowledgebase contains technical information in the form of application notes, technical bulletins, customer publications, presentations, reviews of seminal publications in the field, etc. This documents database contains over one thousand entries and encompasses a wide range of research fields; from plant science to neuroscience. Additionally, all entries have been carefully meta-tagged to improve search results.

“Having served the microRNA research community for the past nine years, we’ve accumulated quite a large library of reference documents such as application notes and related customer publications. This new resource offers the community a simple, user friendly search interface that makes it easier for them to locate the information they’re looking for within that library.” – Chris Hebel (Vice President of Business Development, LC Sciences)

The knowledgebase is freely accessible to all at: http://www.lcsciences.com/Knowledgebase/

Via EPR Network
More Biotech press releases

Microtissues® Inc. and Sigma-Aldrich® Sign Worldwide Supply and Distribution Agreement for the 3D Petri Dish®

Microtissues® Inc. announced today the signing of a Supply and Distribution Agreement with Sigma-Aldrich® Corporation (Nasdaq: SIAL) for the worldwide sales and marketing of the 3D Petri Dish®, a new technology for the culture of living cells in three dimensions (3D). Invented at Brown University, the 3D Petri Dish® maximizes cell-to-cell interactions critical for replicating the function of natural tissues and organs. Shown in numerous peer reviewed papers to work with over fifty different cell types, including cell lines, primary cells and stem cells, the 3D Petri Dish® has applications in cancer research, drug discovery, toxicity testing and regenerative medicine.

“Researchers are rapidly recognizing the importance of 3D cell culture and its ability to reliably mimic in vivo function” said Brian Morgan, Director of Business Development, Microtissues® Inc. “The 3D Petri Dish® creates a natural 3D environment without artificial scaffolds and we’re excited that this distribution agreement will bring our unique and innovative line of products to the worldwide research community.”

Unlike the conventional plastic Petri dish where cells are grown as a thin layer on the surface of the dish, the 3D Petri Dish® forms 3D aggregates of cells. Spheroid size is controlled by the number of cells seeded and hundreds of uniform sized spheroids are formed in a single pipetting step. Spheroids are formed in a well ordered array in a stable platform suitable for long term culture. All spheroids are positioned on the same optical plane making them easy to image (phase contrast, fluorescent). Spheroid size is controlled by the number of cells seeded and a mixture of cells forms mixed spheroids, suitable for investigating tumor-stroma interactions. Spheroids can be grown from single cells, applicable to the study of cancer stem cells. For histology, Western blots and RT-PCR, spheroids are harvested by simply inverting the 3D Petri Dish®. No need to dissolve or digest the gel. The 3D Petri Dish® is a new fundamental tool for the world wide industry of life sciences research.

About Sigma-Aldrich®: Sigma-Aldrich® is a leading Life Science and High Technology company whose biochemical, organic chemical products, kits and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical, diagnostics and high technology manufacturing. Sigma-Aldrich® customers include more than 1.3 million scientists and technologists in life science companies, university and government institutions, hospitals and industry. The Company operates in 38 countries and has nearly 9,000 employees whose objective is to provide excellent service worldwide. Sigma-Aldrich® is committed to accelerating customer success through innovation and leadership in Life Science and High Technology. For more information about Sigma-Aldrich®, please visit its website at www.sigma-aldrich.com.

About Microtissues® Inc: Microtissues® Inc. is a privately held company located in Providence, RI, advancing technologies and applications of 3D cell culture. Microtissues®, Inc.’s products are designed to serve the needs of researchers in a wide range of areas including cancer research, stem cell biology, toxicity testing, developmental biology, drug discovery, regenerative medicine and tissue engineering. Microtissues®, Inc. has an exclusive worldwide license from Brown University to US and international patent applications on the 3D Petri Dish®. For more information on Microtissues®, Inc., please visit www.microtissues.com.

Sigma-Aldrich and Sigma are trademarks of Sigma-Aldrich Co. LLC registered in the US and other countries. Microtissues and 3D Petri Dish are registered trademarks of Microtissues, Inc.

Via EPR Network
More Biotech press releases

Is it a Moment or an Abuse: the Boom of iPSCs Research after 2012 Medicine Nobel Prize

On Creative Biomart website, we can read a report about the 2012 Nobel Prize in Physiology or Medicine regarding the two winners. They bring hope for organ or tissue repair for human or even for rejuvenation, i.e. for long life through induced pluripotent stem cells (iPSCs).

Since the first appearance in 2006, iPSCs became the hit and focus. But there are still lots of unknowns waiting for us before achieving the ideal status. Thus, numerous scientists, researchers and businessmen are struggling and investing for that goal. Here are some examples:

On Dec. 5, 2012, Roche (SIX: RO, ROG; OTCQX: RHHBY) and the Innovative Medicines Initiative (IMI) announced today the launch of StemBANCC, a new academic–industry partnership that unites ten pharmaceutical companies and 23 academic institutions. Initiated and coordinated by Roche and managed by Oxford University, StemBANCC aims to use human induced pluripotent stem cells as research tools for drug discovery with the goal of using this ground-breaking new technology to develop human disease models and enhance drug development.

On Oct. 29, 2012, on the PANS Journal there is an article about Cartilage tissue engineering using differentiated and purified induced pluripotent stem cells.

On Oct. 4, 2012, on Cell Stem Cell, there is a report with the title be Genome Sequencing of Mouse Induced Pluripotent Stem Cells Reveals Retroelement Stability and Infrequent DNA Rearrangement during Reprogramming.

On Jan. 30, 2012, on the PANS Journal, there is a report about modeling hepatitis C virus infection using human induced pluripotent stem cells, which make the individual and tailor therapy further.

Above are only a small part of such studies. People still wonder does it is the moment or an abuse on the iPSCs research. When someone reviewed one of the winners, Shinya Yamanaka, about his opinion on the challenge of iPSCs research, he said, “I have two research directions, the first is to establish human iPSCs bank that comply with clinical application standards. The second is to study the cell mechanism of iPSCs regenerating. And I think the current threat is still to be the safety problem as good research respects both scientific and ethical standards.”

But no one deny the great potential of iPSCs.

Via EPR Network
More Biotech press releases

Gene Therapy and Stem Cell Therapy Standard Developed For A Unique Derivative Of Post Hetero-Plastic Inplantation Chronic Inflammation Syndrome, The NIDO Disease

Researchers task force, led by faculties of T-Protocol, registered Genom Project as controlled genom project in the hosted database of NCBI, a publication matter authority and function assigned organization under oversee of Department of Health & Human Services, reached once to share the exegetical impression officially pre-published concerning the understanding specific spectrum of symptoms covering boroad range of character usually complained and observed through chronic inflammation, granuloma, some types of lymphoma and various uncommon symptoms to let physician scientists suspecting indicium of neurological diseases, NIDO disease, an unique type of post hetero-plastic implantation chronic inflammation syndrome and setting Massachusetts indications of treatments standardized manual (Massachusetts manual) & diagnostic and standardized medical treatment manual for post hetero-plastic inplantation chronic inflammation syndrome, specific edition against NIDO Disease.

The once defined causes of NIDO disease, an unique type of post hetero-plastic implantation chronic inflammation syndrome are considered each of a common living organism to cause conformational diseases like Creutzfeldt-Jakob disease, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and kinds of and a set of biochemical and physical reaction and response realized by cross-species gene- mutation, as biotransformation, easily describing natural physiological and biochemical changes in vivo substrate of human bodies. After this studies, standardized protocol of gene therapy and applied stem cell therapy is now in practice and on available.

Faculties,committing themselves entirely to the project, of each institutes and organizations participating the project to ascertain proteins and DNA/genomic DNA/genom of human, other mammal and virulent microorganism including bacillus/virus affecting each symptom and the symptoms’ spectrum expressed generally and observed commonly on patients suffered from NIDO disease, extraordinarily unique derived type of post hetero-plastic implantation chronic inflammation syndrome and to develop diagnostic standard and treatment protocol standardized and to find a clue compose gene therapy protocol and applied stem cell therapy protocol to entirely heal NIDO disease, an unique type of post hetero-plastic implantation chronic inflammation syndrome and to let all of current suffered patients from various combined symptoms directly derived by chronic inflammation and various tumors, have to express full surprise at the fact that these disease and patients suffered are made up and left no attention and no relief.

Via EPR Network
More Biotech press releases

Nationaly Registered T-Protocol Of Genom Project Successfully Applied To Retrieve Bio Mechanism Of Hair Regrowth

Division of Gene Medicine & Stem Cell Application, School of Medical Science, complete the research and established completely new protocol totally recovering natural bio mechanism of hair regrowth.

The researchers, led by Lord. Prof. Dr. Daichent Otto Rie, specified protein and genom to affect internal bio mechanism to generate hair and control the level of successful growth being low which is the baldness.

The key cast of the set of the bio cycle is hair follicles, which is stem cell on head skin and effect or holding function to cure many neurotic diseases and disorders like Alzheimer’s disease – Prion Disease and even Trion Disease (Post Hetero-Plastic Implantation Chronic Inflammation Syndrome; PhCIS) has absolutely unique character being retrieved absolute stem cell, which can recover the ability as stem cell after got adult. The key genom and DNA has been found through the Genom Project’s T-Protocol research developing in the government registered Genom Project since 2005. The most concentrated attention of researchers is not “what is cause” but “What protocol is best”.

The team of Prof.Daichent has successfully completed in vivo and in vivro experiment actually using voluntary patients whose types of hair loss being across over highly wide range extent to even lymphoma and cancer and finally established next genetic hair loss curing treatment protocol mainly composed of stem cell therapy and gene therapy.

Most of cases are treatable through entry level stem cell theraputic technique or HIV-1 Vector using high level technique but A20 introduction as gene therapy is required when treating patients being suffered from lymphoma, cancer or any neurotic diseases like Alzheimer’s disease – Prion Disease and even Trion Disease (Post Hetero-Plastic Implantation Chronic Inflammation Syndrome; PhCIS).

As Prof.Daichent points since 2005 being on School of Public Health of Harvard, in the treatment manual (published 2005), the key factor to overcome of lymphoma and chronic inflammation on human skin is extraordinary redundancy coding of polyglutamine DNA synthesis as the type of disease caused by pathological proteins and lack or heavy impairment of an specific DNA of A20.

Actually, the treatment protocol curing for baldness is also found through T-protocol which was essentially aimed at achieving causal and complete treatment of lymphoma, cancer, chronic inflammation and many neurotic diseases. Under control over the T-Protocol, all of clinical practitioner must always keep their eyes on the fact of using steroid is taboo over administration so being strictly prohibited. And also the technique must be under control of the competent faculty accredited by board in accordance with Europ.Gene Institute or specifically set physically area solely for research and clinical practice of nations like Switzerland, Germany, India, Hongkong, U.K. territories (NEVER inside U.K.) appointed by protocol developer and assigned practice entity.

Via EPR Network
More Biotech press releases

LC Sciences announced the availability of probe content miRBase 10.0 for their microRNA (miRNA) microarray customers

Taking advantage of its flexible µParaflo™ Chip Technology, Houston based LC Sciences today announced immediate availability of probe content miRBase 10.0 for their microRNA (miRNA) microarray customers. This announcement comes less than a week after Sanger Institute’s update of their sequence database for known miRNAs (miRBase) 1 to version 10.0 (http://microrna.sanger.ac.uk/sequences). As the jump in

version numbers from 9.2 to 10.0 suggests, this update marks a major milestone and features significant changes: 489 new hairpin sequences and 971 novel mature miR and miR* experimentally verified products have been added.

These numbers represent an increase of unique miRNA sequences by 42%. “This exciting increase in data means that researchers using pre-spotted glass arrays with probe content based on versions as recent as 9.1 are missing 49% of mouse, and more than 50% of human sequences, just to give two examples. The other important point is that these sequences are experimentally verified and publicly available data. Unlike with proprietary probe content the researcher has full access and control over the results.” said Chris Hebel, Director of Business Development at LC Sciences.

The importance of this update is emphasized by another aspect of the release: many human, mouse and rat mature miRNAs were renamed and the sequence boundaries changed to reflect the predominant forms identified in recent large-scale cloning studies. The public miRBase sequence database serves as the primary probe content for many commercially available miRNA profiling microarrays. Detection of miRNAs using a microarray offers the opportunity for genome-wide miRNA expression profiling by examining all known miRNA transcripts in a single experiment. However, the continued updating of the database can be problematic for researchers using pre-spotted glass slide arrays as the probe content of the arrays immediately goes out of date whenever a new miRBase version is released. Especially, in a rapidly evolving field as miRNA research it is important to scientists to have the most complete picture of miRNAs expressed in their experimental samples.

LC Sciences miRNA microarrays make use of a microfluidics on-chip synthesis platform, termed µParaFlo™, versus a traditional spotted array based on pre-synthesized oligonucleotides. This on-chip synthesis platform solves the issue of out of date microarrays because made-to-order microarrays can be produced, delivering the most up-to-date research tools to researchers.

In addition to providing much more uniform and reproducible features than a spotted array, on-chip synthesis permits the total customization of content on each individual microarray opening up additional applications such as the discovery of new miRNAs and other small non-coding RNAs.

About microRNA (miRNA)
miRNAs are small non-protein-coding RNA molecules that function as negative regulators of gene expression by base pairing with specific mRNAs. This either inhibits translation or promotes mRNA degradation. About miRBase – The miRBase sequence database is a comprehensive database of miRNA sequence data, annotation, and predicted gene targets and is the primary public repository for these data. Release 10.0 of the database contains 5071 entries representing hairpin precursor miRNAs, expressing 4922 maturemiRNA products, in primates, rodents, birds, fish, worms, flies, plants and viruses (miRBase release summary). miRBase also provides a gene-naming service for assigning official miRNA names to novel miRNAs before they are published. It is freely available to all at http://microrna.sanger.ac.uk/.

About LC Sciences
LC Sciences offers specialty microarray services for nucleic acid/protein profiling and functional analysis, biomarker-discovery, and novel drug screening. Our array service products are based on Atactic Technologies’ µParaflo™ platform technologies that encompass advanced digital chemical synthesis, pico-liter scale biochemical assays, and microfluidic reaction devices containing high density individual 3D chambers.

 

Via EPR Network
More Biotech press releases

CodeLink business assets have been transferred under the agreement between Applied Microarrays and GE Healthcare

Applied Microarrays, Inc announced today the completion of Applied Microarrays’ purchase of certain assets of GE Healthcare’s CodeLinkâ„¢ Gene Expression Bioarray System. Under the terms of the agreement, Applied Microarrays, Inc acquires certain equipment, inventory, licenses and assigned contracts associated with the CodeLink platform. Financial terms were not disclosed.

The transaction enables Applied Microarrays to provide CodeLink users with continued and uninterrupted access to the industry-leading gene expression platform as Applied Microarrays, Inc continues to develop, market, distribute, sell, and support the existing CodeLink catalogue of whole genome expression arrays, Codelink custom arrays and Codelink inside arrays.

Alastair Malcolm, president and chief executive officer of Applied Microarrays, said, “We’re pleased to now have a unique opportunity to launch our company with a full range of microarray design, development, and manufacturing competencies and at the same time ensure a seamless transition for customers.

Eric Roman, General Manager Genomic Sciences, GE Healthcare, said, “There has been strong demand from CodeLink customers to keep these products in the marketplace. We’re delighted to have found a way for our customers to continue working with one of the best gene expression platforms available.”

“The CodeLink platform is customer-proven over several years, notably demonstrating world-class technical performance in the FDA-led MicroArray Quality Control project,” Malcolm said. Applied Microarrays is immediately opening the CodeLink platform to the microarray community for new applications development, offering customers the opportunity to place their unique custom array content on to a robust, proven platform which can be manufactured in high volume.

Applied Microarrays aims to be a leading contract manufacturer of microarrays, of any type, for any customer, with no limitations on substrate material or spotted fluid. “We are fortunate in this regard to have acquired an intact high-capacity microarray spotting facility, employing Six Sigma techniques since its inception to produce leadership quality products,” Malcolm said.

About Applied Microarrays, Inc.
Applied Microarrays is a new company headquartered in Tempe, Arizona. Using the microarray assets acquired from GE, and staffed with experts who developed the CodeLink platform and manufacturing capabilities, the company will specialize in contract development and manufacturing of custom microarrays of all types. The company will additionally continue to offer the CodeLink family of gene expression arrays, and customer-specified subsets of that content on multi-array formats. Our vision is to be the microarray partner of choice for focused “omics” research, and the leading high-volume contract manufacturer for research and diagnostic arrays.

About GE Healthcare
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. GE Healthcare’s expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest.

GE Healthcare’s broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases and other conditions earlier. GE Healthcare’s vision for the future is to enable a new “early health” model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries.

Via EPR Network
More Biotech press releases

Welcome to EPR Biotech News

EPR Biotech News is a new blog, part of EPR Network, that is going to be focused on and will be covering the biotech news and stories from press releases published on EPR Network.

EPR Network (EPR stands for express press release) is one of the nation’s largest press release distribution networks on Web. The EPR’s nationwide network includes 12 State based PR sites, one major PR forum and a number of industry specific PR blogs and what started as a hobby on Internet years ago turned out to be a rapidly growing business today. EPR Network is also known as one of the most trusted (human optimized, published, edited and monitored, spam/scam/low quality PR content free) PR sites on the web with more than 10,000 company and individual press releases distributed per month. EPR Network is putting your press releases on top of all major search engines’ results and is reaching thousands of individuals, companies, PR specialists, media professionals, bloggers and journalists every day.

EPR Network has thousands of clients around the world including global 500 corporations like Hilton Hotels, Barclays Bank, AXA Insurance, Tesco UK, eBay/Skype, Emirates, just to name a few. The network’s PR web sites are currently reaching from 150,000 to sometimes 500,000 unique visitors per month while our viral reach could possibly go to as much as 1M people per month through our presence across various social media sites. EPR Network was established in 2004 and as of May 2008 it had more than 800,000 press releases (pages) published on its network.

If you have a press release to be distributed, you can do it over here: press release distribution